Delivery Order SPE2DB20D3101-SPE2DB22FH8Y7
- Not listed
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Lantus Solostar 100 unit/mL 3mL, a specialty medication used for diabetes management. The $8,165.04 Firm Fixed Price Delivery Order contract has a completion date of February 14, 2023. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract...
- This federal contract award, valued at $2,547.68, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Lantus Solostar 100 unit/mL 3mL, a specialty medication used for diabetes management. The contract type is a Delivery Order with a Firm Fixed Price pricing structure. The award has a period of performance through March 27, 2024, and was not set aside for any specific business category....
- This federal contract award to Amerisourcebergen Drug Corp (a subsidiary of Cencora, Inc.) is a delivery order valued at $1,242.64 for the provision of Lantus Solostar 100 unit/mL 3mL medication. The award was made by the Defense Logistics Agency (DLA), a defense agency, on September 29, 2021, with a completion date of September 30, 2021. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle...
- This federal contract award to Amerisourcebergen Drug Corp, a wholly-owned subsidiary of Cencora, Inc., was issued by the Defense Logistics Agency (DLA) for the delivery of Lantus Solostar 100 Unit/ML 3ML, a specialty medication used for diabetes management. The firm-fixed-price delivery order, valued at $3,054.34, has a period of performance through May 2, 2023. This award is not designated as a set-aside contract. Amerisourcebergen Drug Corp holds a substantial Indefinite Delivery Contract...
- This federal contract award from the Defense Logistics Agency (DLA) was made to Amerisourcebergen Drug Corp, a subsidiary of the pharmaceutical distribution company Cencora, Inc. The $2,607.30 firm-fixed-price delivery order is for the supply of Lantus Solostar 100 unit/mL 3mL, a diabetes medication. The contract has an ultimate completion date of November 15, 2022 and was awarded on November 14, 2022. It is not designated as a set-aside contract. Amerisourcebergen holds a significant...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Lantus Solostar 100 unit/mL 3mL medication. The $4,629.96 firm fixed-price delivery order was awarded on October 30, 2021, with a completion date of November 1, 2021. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The award has a ceiling value of $1,587.03 and covers the delivery of Lantus Solostar 100 unit/ml 3ml, a medication used to treat diabetes. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued up to $999,999,999.00 and running through...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is a Delivery Order valued at $6,065.55 for the purchase of Lantus Solostar 100 Unit/mL 3mL, a medication used to treat diabetes. The contract has a Period of Performance through May 2, 2023 and does not have a set-aside designation, indicating it was awarded through full and open competition. Amerisourcebergen Drug Corp is a major pharmaceutical...
- This federal contract award, valued at $13,355.86, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Lantus Solostar 100 unit/mL 3mL, a specialty pharmaceutical product used for diabetes management. The award is a firm fixed-price delivery order with a completion date of February 13, 2024. The contract was made through full and open competition, with no set-aside designation. Amerisourcebergen Drug...
- This federal contract award, valued at $3,682.91, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Lantus Solostar 100 unit/ml 3ml, a specialty medication used for the treatment of diabetes. The contract is a Firm Fixed Price Delivery Order with a period of performance through March 1, 2024. It is not designated as a set-aside contract. Amerisourcebergen Drug Corp holds a significant Indefinite...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB22FH8Y7Delivery Order
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for the delivery of Lantus Solostar 100 unit/mL 3mL, a prescription medication used to treat diabetes. The contract, valued at $1,339.60, was awarded on February 23, 2022, with a completion date of February 24, 2022. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition. Cencora, Inc., the parent company of Amerisourcebergen Drug Corp, also holds a smaller IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 2/23/22 |